{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T19:55:59Z","timestamp":1788638159303,"version":"build-2803163510"},"reference-count":40,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Clinically evident portal hypertension (CEPH) is a major risk factor for the development and poor outcomes of hepatocellular carcinoma (HCC). The aim of this study was to determine the impact of CEPH on the risk of HCC recurrence following liver transplantation (LT). Methods: A total of 129 HCC patients were included in this retrospective analysis. The definition of CEPH was based on indirect clinical features without hepatic venous pressure gradient measurement. The impact of CEPH on the post-LT risk of HCC recurrence was determined by uni- and multivariate analysis. Results: Evidence of manifest portal hypertension (PH) was associated with a higher 18F-fluorodeoxy-glucose (FDG) uptake of HCC on positron emission tomography (PET; p &lt; 0.001) and increased serum levels of C-reactive protein (p = 0.008) and interleukin\u22126 (IL-6; p = 0.001). The cumulative risk of HCC recurrence at 5 years post-LT was significantly higher in the CEPH group (38.1% vs. 10.6%, p &lt; 0.001). The eligibility for neoadjuvant transarterial chemoembolization (TACE) was comparable between both study cohorts (71.4% vs. 74.2%; p = 0.719). However, the post-interventional pathologic response rate was significantly lower in the case of PH (15.6% vs. 53.1%; p &lt; 0.001). In addition to the Milan criteria (MC), 18F-FDG avidity on PET and serum values of IL-6 and alfa-fetoprotein, we identified CEPH as another significant and independent predictor of HCC recurrence (p = 0.008). Conclusions: CEPH correlates with an unfavorable tumor phenotype, TACE refractoriness and a risk of post-LT HCC recurrence. Therefore, the clinical features of PH should be implemented in pre-transplant risk assessment and decision-making processes.<\/jats:p>","DOI":"10.3390\/jcm14062032","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T06:36:23Z","timestamp":1742193383000},"page":"2032","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinically Evident Portal Hypertension Is an Independent Risk Factor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3438-8969","authenticated-orcid":false,"given":"Arno","family":"Kornberg","sequence":"first","affiliation":[{"name":"Department of Surgery, Klinikum Rechts der Isar, Technical University of Munich (TUM), Ismaninger Str. 22, 81675 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3625-784X","authenticated-orcid":false,"given":"Nick","family":"Seyfried","sequence":"additional","affiliation":[{"name":"Department of Surgery, Klinikum Rechts der Isar, Technical University of Munich (TUM), Ismaninger Str. 22, 81675 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Friess","sequence":"additional","affiliation":[{"name":"Department of Surgery, Klinikum Rechts der Isar, Technical University of Munich (TUM), Ismaninger Str. 22, 81675 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1111\/jgh.16693","article-title":"Recurrence risk prediction models for hepatocellular carcinoma after liver transplantation","volume":"39","author":"Zhang","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/lt.26392","article-title":"Lower Alpha-Fetoprotein Threshold of 500 ng\/mL for Liver Transplantation May Improve Posttransplant Outcomes in Patients With Hepatocellular Carcinoma","volume":"28","author":"Goldman","year":"2022","journal-title":"Liver Transpl."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.hpb.2019.04.017","article-title":"Pathologic complete response to chemoembolization improves survival outcomes after curative surgery for hepatocellular carcinoma: Predictive factors of response","volume":"21","author":"Yang","year":"2019","journal-title":"HPB"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/lt.22416","article-title":"Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation","volume":"18","author":"Kornberg","year":"2012","journal-title":"Liver Transpl."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Gr\u0105t, K., Pacho, R., Gr\u0105t, M., Krawczyk, M., Zieniewicz, K., and Rowi\u0144ski, O. (2019). Impact of Body Composition on the Risk of Hepatocellular Carcinoma Recurrence After Liver Transplantation. J. Clin. Med., 13.","DOI":"10.3390\/jcm8101672"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000533857","article-title":"Impact of Liver Fibrosis Severity on Oncological Prognosis in Hepatocellular Carcinoma","volume":"13","author":"Yasukawa","year":"2023","journal-title":"Liver Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/liv.14977","article-title":"Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses","volume":"41","author":"Allaire","year":"2021","journal-title":"Liver Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ueg2.12188","article-title":"Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization","volume":"10","author":"Hahn","year":"2022","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jhep.2009.01.014","article-title":"Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis","volume":"50","author":"Ripoll","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ejso.2022.11.005","article-title":"Clinically significant portal hypertension (CSPH) on early-stage HCC following hepatectomy: What\u2019s the impact?","volume":"49","author":"Xia","year":"2023","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Dioguardi Burgio, M., Garzelli, L., Cannella, R., Ronot, M., and Vilgrain, V. (2023). Hepatocellular Carcinoma: Optimal Radiological Evaluation before Liver Transplantation. Life, 13.","DOI":"10.3390\/life13122267"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijsu.2019.07.035","article-title":"FDG-PET predicted unfavorable tumor histology in living donor liver transplant recipients; a retrospective cohort study","volume":"69","author":"Ling","year":"2019","journal-title":"Int. J. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jhep.2020.10.004","article-title":"Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality","volume":"74","author":"Costa","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kornberg, A., Witt, U., Matevossian, E., K\u00fcpper, B., Assfalg, V., Drzezga, A., H\u00fcser, N., Wildgruber, M., and Friess, H. (2013). Extended postinterventional tumor necrosis-implication for outcome in liver transplant patients with advanced HCC. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0053960"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1007\/s00330-017-5145-9","article-title":"Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma","volume":"28","author":"Choi","year":"2018","journal-title":"Eur. Radiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrgastro.2016.193","article-title":"Liver transplantation for hepatocellular carcinoma: Outcomes and novel surgical approaches","volume":"14","author":"Sapisochin","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/jso.25721","article-title":"The role of preoperative albumin-bilirubin grade for oncological risk stratification in liver transplant patients with hepatocellular carcinoma","volume":"120","author":"Kornberg","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2020.10.033","article-title":"A novel waitlist dropout score for hepatocellular carcinoma\u2014Identifying a threshold that predicts worse post-transplant survival","volume":"74","author":"Mehta","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/hep.27864","article-title":"Impact of clinically evident portal hypertension on the course of hepatocellular carcinoma in patients listed for liver transplantation","volume":"62","author":"Faitot","year":"2015","journal-title":"Hepatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/MCG.0000000000000671","article-title":"Prognostic Significance of Hemodynamic and Clinical Stages in the Prediction of Hepatocellular Carcinoma","volume":"51","author":"Suk","year":"2017","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1097\/MEG.0b013e32832a21c1","article-title":"Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis","volume":"21","author":"Kim","year":"2009","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6268","DOI":"10.21037\/qims-22-1420","article-title":"The application of (18)F-FDG PET\/CT imaging for human hepatocellular carcinoma: A narrative review","volume":"13","author":"Yao","year":"2023","journal-title":"Quant. Imaging Med. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00259-019-04638-4","article-title":"Hypoxia-induced modulation of glucose transporter expression impacts (18)F-fluorodeoxyglucose PET-CT imaging in hepatocellular carcinoma","volume":"47","author":"Xia","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_24","first-page":"675","article-title":"Role of Hydrogen Sulfide and Hypoxia in Hepatic Angiogenesis of Portal Hypertension","volume":"28","author":"Yang","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Oura, K., Morishita, A., Tadokoro, T., Fujita, K., Tani, J., and Kobara, H. (2024). Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor Inhibition in Hepatocellular Carcinoma. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252413590"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1007\/s00259-023-06251-y","article-title":"SUVmax on 18F-FDG PET and PD-L1 expression between in hepatocellular carcinoma","volume":"50","author":"Zhou","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wang, Y., Li, Z., Huang, Z., Yu, X., Zheng, L., and Xu, J. (2022). C-Reactive Protein Is an Indicator of the Immunosuppressive Microenvironment Fostered by Myeloid Cells in Hepatocellular Carcinoma. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.774823"},{"key":"ref_28","first-page":"7158","article-title":"Association between the expression levels of IL-6 and IL-6R in the hepatocellular carcinoma microenvironment and postoperative recurrence","volume":"16","author":"Zhang","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Minici, R., Siciliano, M.A., Ammendola, M., Santoro, R.C., Barbieri, V., Ranieri, G., and Lagan\u00e0, D. (2022). Prognostic Role of Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR), Platelet-to-Lymphocyte Ratio (PLR) and Lymphocyte-to-C Reactive Protein Ratio (LCR) in Patients with Hepatocellular Carcinoma (HCC) undergoing Chemoembolizations (TACE) of the Liver: The Unexplored Corner Linking Tumor Microenvironment, Biomarkers and Interventional Radiology. Cancers, 15.","DOI":"10.3390\/cancers15010257"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"He, Q., Yang, J., and Jin, Y. (2022). Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.869993"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jceh.2021.12.009","article-title":"Transarterial Chemoembolization (TACE) Combined With Sorafenib versus TACE in Patients With BCLC Stage C Hepatocellular Carcinoma\u2014A Retrospective Study","volume":"12","author":"Patidar","year":"2022","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jhep.2021.11.013","article-title":"The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma","volume":"76","author":"Granito","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"El Hajji, S., Lacotte, S., Moeckli, B., Cauchy, F., Compagnon, P., and Toso, C. (2024). Transjugular Intrahepatic Portosystemic Shunt Is Associated With Better Waitlist Management of Liver Transplant Candidates With Hepatocellular Carcinoma. Transpl. Int., 37.","DOI":"10.3389\/ti.2024.12781"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Allaire, M., Garcia, H., Meyblum, L., Mouri, S., Spitzer, E., Goumard, C., Lucidarme, O., Rudler, M., Scatton, O., and Roux, C. (2025). Non selective beta-blockers prevent PHT-related complications occurrence in HCC patients with esophageal varices treated by TACE. Clin. Res. Hepatol. Gastroenterol., 49.","DOI":"10.1016\/j.clinre.2024.102496"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Wei, G., Zhao, Y., Feng, S., Yuan, J., Xu, G., Lv, T., Yang, J., Kong, L., and Yang, J. (2024). Does depressurization of the portal vein before liver transplantation affect the recurrence of HCC? A nested case-control study. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12322-6"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2024.05.037","article-title":"Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation","volume":"81","author":"Li","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jhep.2013.07.012","article-title":"Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma","volume":"59","author":"Tsochatzis","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"645","DOI":"10.5604\/01.3001.0012.0948","article-title":"Rapamycin Combi with TAE on the Growth, Metastasis, and Prognosis of Hepatocellular Carcinoma in Rat Models","volume":"17","author":"Lei","year":"2018","journal-title":"Ann. Hepatol."},{"key":"ref_39","first-page":"46","article-title":"The Impact of Portal Hypertension Assessment Method on the Outcomes of Hepatocellular Carcinoma Resection: A Meta-Analysis of Matched Cohort and Prospective Studies","volume":"280","author":"Aliseda","year":"2024","journal-title":"Ann. Surg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jhep.2023.12.028","article-title":"Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient","volume":"80","author":"Jachs","year":"2024","journal-title":"J. Hepatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/2032\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:54:55Z","timestamp":1760028895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/2032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14062032"],"URL":"https:\/\/doi.org\/10.3390\/jcm14062032","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]}}}